Success Metrics

Clinical Success Rate
86.7%

Based on 13 completed trials

Completion Rate
87%(13/15)
Active Trials
0(0%)
Results Posted
85%(11 trials)
Terminated
2(13%)

Phase Distribution

Ph not_applicable
1
7%
Ph phase_2
4
27%
Ph phase_1
10
67%

Phase Distribution

10

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
10(66.7%)
Phase 2Efficacy & side effects
4(26.7%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

86.7%

13 of 15 finished

Non-Completion Rate

13.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(13)
Terminated(2)

Detailed Status

Completed13
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
86.7%
Most Advanced
Phase 2

Trials by Phase

Phase 110 (66.7%)
Phase 24 (26.7%)
N/A1 (6.7%)

Trials by Status

completed1387%
terminated213%

Recent Activity

0 active trials
Showing 5 of 15
terminatedphase_2

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

NCT02111096
completedphase_1

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

NCT01836198
completedphase_1

The Effects of LY2409021 on the Liver

NCT01588366
completedphase_1

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

NCT01460368
completedphase_1

Study of LY2409021 in Participants With Type 1 Diabetes

NCT01640834
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT02111096Phase 2

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Terminated
NCT01836198Phase 1

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

Completed
NCT01588366Phase 1

The Effects of LY2409021 on the Liver

Completed
NCT01460368Phase 1

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

Completed
NCT01640834Phase 1

Study of LY2409021 in Participants With Type 1 Diabetes

Completed
NCT01929109Phase 1

A Study of LY2409021 in Participants With Different Levels of Kidney Function

Completed
NCT02217618Phase 1

A Study of LY2409021 in Healthy Participants

Completed
NCT02385084Phase 1

A Study of LY2409021 Formulations in Healthy Participants

Terminated
NCT02091362Phase 2

A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus

Completed
NCT01241448Phase 2

A Study of LY2409021 in Patients With Type 2 Diabetes

Completed
NCT00871572Phase 2

A Study for Participants With Type 2 Diabetes Mellitus

Completed
NCT02669524Not Applicable

Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes

Completed
NCT01606423Phase 1

The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants

Completed
NCT01606397Phase 1

A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes

Completed
NCT01606371Phase 1

A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15